Literature DB >> 8530529

Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder.

S D Yang1, J S Yu, T T Lee, C C Yang, M H Ni, Y Y Yang.   

Abstract

As compared to normal people, the lymphocytes of patients with schizophrenia were found to have an impairment of ATP.Mg-dependent protein phosphatase activation. More importantly, the impaired protein phosphatase activation in the lymphocytes of schizophrenic patients could be consistently and completely restored to normal by exogenous pure protein kinase FA/glycogen synthase kinase-3 alpha (kinase FA/GSK-3 alpha) (the activating factor of ATP.Mg-dependent protein phosphatase), indicating that the molecular mechanism for the impaired protein phosphatase activation in schizophrenic patients may be due to a functional loss of kinase FA/GSK-3 alpha. Immunoblotting and kinase activity analysis in an anti-kinase FA/GSK-3 alpha immunoprecipitate further demonstrate that both cellular activities and protein levels of kinase FA/GSK-3 alpha in the lymphocytes of schizophrenic patients were greatly impared as compared to normal controls. Statistical analysis revealed that the lymphocytes isolated from 37 normal people contain kinase FA/GSK-3 alpha activity in the high levels of 14.8 +/- 2.4 units/mg of cell protein, whereas the lymphocytes of 48 patients with schizophrenic disorder contain kinase FA/GSK-3 alpha activity in the low levels of 2.8 +/- 1.6 units/mg, indicating that the different levels of kinase FA/GSK-3 alpha activity between schizophrenic patients and normal people are statistically significant. Taken together, the results provide initial evidence that patients with schizophrenic disorder may have a common impairment in the protein levels and cellular activities of kinase FA/GSK-3 alpha, a multisubstrate protein kinase and a multisubstrate protein phosphatase activator in their lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530529     DOI: 10.1002/jcb.240590112

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response.

Authors:  Renan P Souza; Marco A Romano-Silva; Jeffrey A Lieberman; Herbert Y Meltzer; Albert H C Wong; James L Kennedy
Journal:  Psychopharmacology (Berl)       Date:  2008-05-26       Impact factor: 4.530

2.  AKT/GSK3 signaling pathway and schizophrenia.

Authors:  Effat S Emamian
Journal:  Front Mol Neurosci       Date:  2012-03-15       Impact factor: 5.639

3.  Neurodevelopment in schizophrenia: the role of the wnt pathways.

Authors:  Isabella Panaccione; Flavia Napoletano; Alberto Maria Forte; Giorgio D Kotzalidis; Antonio Del Casale; Chiara Rapinesi; Chiara Brugnoli; Daniele Serata; Federica Caccia; Ilaria Cuomo; Elisa Ambrosi; Alessio Simonetti; Valeria Savoja; Lavinia De Chiara; Emanuela Danese; Giovanni Manfredi; Delfina Janiri; Marta Motolese; Ferdinando Nicoletti; Paolo Girardi; Gabriele Sani
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

4.  Deconstructing GSK-3: The Fine Regulation of Its Activity.

Authors:  Miguel Medina; Francisco Wandosell
Journal:  Int J Alzheimers Dis       Date:  2011-04-28

Review 5.  Dopaminergic intracellular signal integrating proteins: relevance to schizophrenia.

Authors:  Bruno R Souza; Renan P Souza; Daniela V F Rosa; Melissa M Guimarães; Humberto Correa; Marco A Romano-Silva
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

6.  MENA is a transcriptional target of the Wnt/beta-catenin pathway.

Authors:  Ayaz Najafov; Tuncay Seker; Ipek Even; Gerta Hoxhaj; Osman Selvi; Duygu Esen Ozel; Ahmet Koman; Necla Birgül-İyison
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

7.  The Frizzled 3 gene is associated with methamphetamine psychosis in the Japanese population.

Authors:  Makiko Kishimoto; Hiroshi Ujike; Yuko Okahisa; Tatsuya Kotaka; Manabu Takaki; Masafumi Kodama; Toshiya Inada; Mitsuhiko Yamada; Naohisa Uchimura; Nakao Iwata; Ichiro Sora; Masaomi Iyo; Norio Ozaki; Shigetoshi Kuroda
Journal:  Behav Brain Funct       Date:  2008-08-15       Impact factor: 3.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.